Education
About Us
Working with TipRanks
Follow Us
Acrux Limited (ARUXF)
OTHER OTC:ARUXF
ARUXF Stock Chart & Stats
$0.01
<$0.01(41.59%)
At close: 4:00 PM EST
$0.01
<$0.01(41.59%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume500.00
Average Volume (3M)5.33K
Market Cap
$3.90M
Enterprise Value$8.24M
Total Cash (Recent Filing)$863.00K
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)9.3
Beta1.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding410,608,520
10 Day Avg. Volume6,100
30 Day Avg. Volume5,333
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market Cap2.11
Enterprise Value/Revenue6.92
Enterprise Value/Gross Profit-7.37
Enterprise Value/Ebitda-0.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Licensing / Royalty Business ModelAcrux’s partner-led licensing model is structurally durable: it reduces capital intensity and commercial execution risk by leveraging partners' sales and regulatory infrastructure. Recurring royalties and milestone payments provide scalable, high-margin revenue when partnered products succeed.
Recent Top-line GrowthMaterial revenue growth in 2025 signals improving commercial traction or milestone recognition under licensing deals. Sustained top-line expansion strengthens the platform’s ability to secure future partner deals, trigger contingent payments, and improve runway absent major new capital raises.
Very High Reported Gross MarginA 100% gross margin reflects the dominance of licensing and low-cost revenue streams versus product manufacture. This structural margin profile implies high incremental profitability on additional licensing income and favors cash conversion if operating expenses are controlled.
Bears Say
High Financial LeverageA debt-to-equity ratio above 3x denotes elevated leverage that materially increases refinancing and solvency risk. High fixed financing costs limit flexibility to invest in development, fund operations between milestones, or absorb adverse commercial setbacks without dilutive capital actions.
Negative Operating And Free Cash FlowOngoing negative operating cash flow indicates the business burns cash to run operations and relies on financing, upfronts or milestones to fund activity. Even with modest free cash flow improvement, persistent cash deficits threaten liquidity and heighten dependence on external funding.
Persistent Losses / Negative ProfitabilitySustained net losses and negative operating margins undermine retained earnings and make it harder to self-fund development or defend programs. Long-term unprofitability increases the likelihood of restructures, partner renegotiations, or further equity/debt raises that dilute existing stakeholders.
Acrux News
ARUXF FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is $3.90M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 167 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of $0.063 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 410,608,520 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in ARUXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-270.27%
Trailing 12-Months
Asset Growth
-18.83%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Technical Analysis
Living Cell Technologies
―
Invex Therapeutics Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―
Ownership Overview
Options Prices
Currently, No data available
---